Search
Ergoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [T90] The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives
Mixtures: TOTERJİN DAMLA, 50 CCCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLithium carbonate
go.drugbank.com/drugs/DB14509ApprovedInvestigationalLithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexProducts: ESKALIT® SR 450 MG, LITHURIL 300 MG KAPSUL, 100 ADETValaciclovir
go.drugbank.com/drugs/DB00577ApprovedInvestigationalValacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class [F3949]. … Genital herpes is a frequently diagnosed sexually transmitted disease which currently affects more than 400 million individuals worldwide.
Categories: Heterocyclic Compounds, 2-RingSynonyms: L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester, L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanineHydrocortisone succinate
go.drugbank.com/drugs/DB14545ApprovedInvestigationalCategories: 17-Hydroxycorticosteroids, Cytochrome P-450 SubstratesProducts: SOLU-CORTEF® 100 MG POLVO PARA INYECCION, SOLU-CORTEF FOR INJECTION 100 mg/vialNevirapine
go.drugbank.com/drugs/DB00238ApprovedInvestigationalA potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS.
Mixtures: TRIVIRO LNS® LAMIVUDINA 150 MG NEVIRAPINA 200 MG ESTAVUDINA 40 MG, LAMIVUDINA 150 MG + ZIDOVUDINA 300 MG + NEVIRAPINA 200 MG TABLETAS CUBIERTASCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersClofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnClofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. … It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids.
Categories: Heterocyclic Compounds, 3-Ring, Cytochrome P-450 CYP2C8 InhibitorsProducts: Fazim 50 mg Capsule, CLOFZIMIN® 100 MGBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalBinimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib]. … [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: MEKTOVI® 15 MG TABLETAS RECUBIERTAS, Mektovı 15 mg Film Kaplı Tablet, 84 ADETTafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigational[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Synonyms: 2-(3,5-Dichlorophenyl)benzoxazole-6-carboxylic acid, 6-BENZOXAZOLECARBOXYLIC ACID, 2-(3,5-DICHLOROPHENYL)-Categories: Heterocyclic Compounds, 2-RingAfatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationalAfatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: GIOTRIF® 50 MG, GIOTRIF® 30 MGAgalsidase alfa
go.drugbank.com/drugs/DB15874ApprovedInvestigational[A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413] … Agalsidase alfa is a recombinant human α-galactosidase A similar to [agalsidase beta].
Synonyms: alpha-D-galactosidase, alpha-galactosidase AProducts: REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML